A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study (A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs KLS 2031 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Kolon Life Science
Most Recent Events
- 08 Jul 2024 Planned primary completion date changed from 30 Oct 2026 to 30 Aug 2026.
- 08 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2022 New trial record